These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10155675)

  • 81. Treatment of reflux oesophagitis with ranitidine.
    Wesdorp IC; Dekker W; Klinkenberg-Knol EC
    Gut; 1983 Oct; 24(10):921-4. PubMed ID: 6311693
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Managing heartburn at the 'base' of the GERD 'iceberg': effervescent ranitidine 150 mg b.d. provides faster and better heartburn relief than antacids.
    Earnest D; Robinson M; Rodriguez-Stanley S; Ciociola AA; Jaffe P; Silver MT; Kleoudis CS; Murdock RH
    Aliment Pharmacol Ther; 2000 Jul; 14(7):911-8. PubMed ID: 10886047
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Prolonged remission of oesophagitis does not alter the magnitude of oesophageal acid exposure.
    Singh P; Taylor RH; Colin-Jones DG
    Scand J Gastroenterol; 1994 Jan; 29(1):11-6. PubMed ID: 8128170
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Restore Investigator Group.
    Smith PM; Kerr GD; Cockel R; Ross BA; Bate CM; Brown P; Dronfield MW; Green JR; Hislop WS; Theodossi A
    Gastroenterology; 1994 Nov; 107(5):1312-8. PubMed ID: 7926495
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Medical or surgical therapy for erosive reflux esophagitis: cost-utility analysis using a Markov model.
    Romagnuolo J; Meier MA; Sadowski DC
    Ann Surg; 2002 Aug; 236(2):191-202. PubMed ID: 12170024
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Cost effectiveness of medical versus surgical treatment in patients with severe or refractory gastroesophageal reflux disease in the Netherlands.
    Van Den Boom G; Go PM; Hameeteman W; Dallemagne B; Ament AJ
    Scand J Gastroenterol; 1996 Jan; 31(1):1-9. PubMed ID: 8927933
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain.
    Ofman JJ; Gralnek IM; Udani J; Fennerty MB; Fass R
    Am J Med; 1999 Sep; 107(3):219-27. PubMed ID: 10492314
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Meta-Analyses of Cisapride, Omeprazole and Ranitidine in the Treatment of GORD: Implications for Treating Patient Subgroups.
    Iskedjian M; Einarson TR
    Clin Drug Investig; 1998; 16(1):9-18. PubMed ID: 18370513
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Assessing the cost-effectiveness of medical treatments in acid-related diseases. The Markov chain approach applied to a comparison between intermittent and maintenance treatment of reflux esophagitis.
    Stålhammar NO
    Scand J Gastroenterol Suppl; 1993; 199():8-13. PubMed ID: 8171303
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Clinical and economic factors in the selection of drugs for gastroesophageal reflux disease.
    Bate CM; Richardson PD
    Pharmacoeconomics; 1993 Feb; 3(2):94-9. PubMed ID: 10146958
    [No Abstract]   [Full Text] [Related]  

  • 91. Histological esophagitis: clinical and histological response to omeprazole in children.
    Strauss RS; Calenda KA; Dayal Y; Mobassaleh M
    Dig Dis Sci; 1999 Jan; 44(1):134-9. PubMed ID: 9952234
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis.
    Heudebert GR; Marks R; Wilcox CM; Centor RM
    Gastroenterology; 1997 Apr; 112(4):1078-86. PubMed ID: 9097989
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Sample size calculation in economic evaluations.
    Al MJ; van Hout BA; Michel BC; Rutten FF
    Health Econ; 1998 Jun; 7(4):327-35. PubMed ID: 9683093
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis.
    Harvey RF; Gordon PC; Hadley N; Long DE; Gill TR; Macpherson RI; Beats BC; Tottle AJ
    Lancet; 1987 Nov; 2(8569):1200-3. PubMed ID: 2890820
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Proton pump inhibitors in acute treatment of reflux oesophagitis : a cost-effectiveness analysis.
    Lucioni C; Mazzi S; Rossi C
    Clin Drug Investig; 2005; 25(5):325-36. PubMed ID: 17532670
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Economic evaluation of long-term management strategies for erosive oesophagitis.
    Goeree R; O'Brien B; Hunt R; Blackhouse G; Willan A; Watson J
    Pharmacoeconomics; 1999 Dec; 16(6):679-97. PubMed ID: 10724795
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Preoperative ranitidine and metoclopramide.
    Pond W; Lindsey R; Cowan J
    Anesth Analg; 1987 Nov; 66(11):1202. PubMed ID: 3662074
    [No Abstract]   [Full Text] [Related]  

  • 98. Quality problems that result in adverse outcomes provide opportunities for quality improvement.
    Int J Qual Health Care; 1996 Dec; 8(6):597-8. PubMed ID: 9007609
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The Safety and Efficacy of Lansoprazole plus Metoclopramide among Neonates with Gastroesophageal Reflux Disease Resistant to Conservative Therapy and Monotherapy: A Clinical Trial.
    Taheri PA; Validad E; Eftekhari K
    Int J Pediatr; 2021; 2021():3208495. PubMed ID: 33510798
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Treatment of oesophagitis in scleroderma with omeprazole.
    Olive A; Maddison PJ; Davis M
    Br J Rheumatol; 1989 Dec; 28(6):553. PubMed ID: 2590816
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.